Veeva Systems Inc. (VEEV) 株式分析

企業概要

Veeva Systems Inc. is a prominent provider of cloud-based software solutions specifically designed for the life sciences sector, serving clients across North America, Europe, the Asia Pacific region, as well as markets in the Middle East, Africa, and Latin America. The enterprise operates within the Healthcare sector and functions as a key player in the Health Information Services industry, delivering essential digital infrastructure for pharmaceutical and biotechnology firms to manage their commercial operations. Veeva's market capitalization stands at $27.38B, supported by an annual revenue of $3.20B and a substantial workforce of 7,928 employees. These financial figures indicate that the company has achieved significant scale and market penetration, positioning it as a major entity with a robust market cap that reflects high investor confidence in its recurring revenue model and technological dominance within the specialized health information services landscape.

財務健全性

The company reported a trailing twelve-month revenue of $3.20B, generating a net income of $908.91M and an EBITDA of $984.97M, revealing a cost structure where net income is approximately 28.4% of revenue due to significant operating expenses including research and development and sales costs. Veeva demonstrated strong operational efficiency by producing $1.05B in free cash flow, which provides the financial flexibility to fund ongoing R&D initiatives, invest in cloud infrastructure expansion, and potentially pursue strategic acquisitions without relying heavily on external capital markets. The company maintains exceptional profitability metrics, with a gross margin of 75.5% indicating high pricing power and low cost of goods sold typical of software-as-a-service models, an operating margin of 29.4% reflecting efficient management of overhead and administrative expenses, and a profit margin of 28.4% that underscores the effectiveness of converting revenue into bottom-line earnings. On the balance sheet, Veeva holds $6.56B in cash against a minimal debt load of $95.86M, resulting in a conservative debt-to-equity ratio of 1.33 and indicating a highly leveraged-free structure that minimizes interest rate risk. This liquidity position is further reinforced by a current ratio of 4.88, which signifies a very strong short-term liquidity posture where current assets vastly exceed current liabilities, ensuring the ability to meet obligations as they fall due. Additionally, the return on equity of 13.9% and return on assets of 7.3% highlight management's effectiveness in generating returns on shareholders' capital and utilizing the company's asset base to drive profitability relative to industry peers.

バリュエーション評価

Veeva Systems Inc. is valued with a trailing P/E ratio of 30.56 and a forward P/E of 16.85, implying that the market expects earnings to grow significantly in the coming year, as the forward multiple is substantially lower than the trailing multiple. The price-to-book ratio stands at 3.78, indicating that the stock trades at a considerable premium to its book value, which is typical for high-growth technology firms with intangible assets like proprietary software and intellectual property that are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 8.57 and an EV/EBITDA of 21.06 suggest that the market is willing to pay a high multiple for revenue and earnings, reflecting expectations of sustained top-line expansion and strong cash conversion. The stock's price range over the last year has oscillated between a 52-week low of $166.30 and a 52-week high of $310.50, providing a context for assessing current valuation levels against recent historical volatility. With a beta of 1.10, the stock exhibits price volatility that is slightly higher than the broader market, meaning that VEEV tends to experience larger price swings than the S&P 500 during periods of market stress or rally.

Growth & Income

Veeva Systems Inc. has demonstrated robust top-line momentum with revenue growth of 16.0% year-over-year and earnings growth of 23.2% year-over-year, indicating that earnings are expanding at a faster pace than revenue, which often signals improving operating leverage and margin expansion as fixed costs are spread over a larger revenue base. As the company does not currently pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all of its earnings to reinvest into high-priority areas such as product development, global market expansion, and cloud infrastructure scaling rather than distributing cash to shareholders. This reinvestment strategy is characteristic of a growth-stage technology company prioritizing long-term market share consolidation and innovation over immediate income generation for investors. Overall, the company presents a profile characterized by double-digit revenue growth, accelerating earnings expansion, and a capital allocation strategy focused entirely on fueling future organic growth and technological advancement within the life sciences software ecosystem.